🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the battle against superbug strains of the infection, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are escalating around the world, with estimates suggesting in excess of 82 million new cases annually. Especially elevated rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, the spread of superbugs and the highly restricted therapeutic options at this time.”

Public health authorities are deeply concerned about the rise in treatment-resistant strains. The WHO has classified it as a "critical concern". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Secure Authorization

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This medication, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This authorization represents a huge turning point in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Outcomes and Global Access

Based on data released by a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which combines a dual-drug approach. The research involved hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the rights to license and sell the drug in a wide range of regions with limited resources.

Clinicians directly involved have expressed positive views. Access to a one-pill regimen such as this is seen as a "game-changer" for managing the epidemic. This is viewed as essential to lessen the impact of the illness for patients and to prevent the spread of untreatable gonorrhoea globally.